logo-loader
e-Therapeutics plc

e-Therapeutics continuing to convert business development into cash generating partnerships

e-Therapeutics PLC's (LON:ETX) Ray Barlow says they're actively engaged in exploring all organic and non-organic opportunities that have the potential to create incremental value for its shareholders.

He adds that multiple proposals for its artificial intelligence-based drug research products have been sent to potential partners and customers.

Quick facts: e-Therapeutics plc

Price: 2.55 GBX

Market: AIM
Market Cap: £6.86 m
Follow

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of e-Therapeutics plc named herein, including the promotion by the Company of e-Therapeutics plc in any Content on the Site, the Company receives...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: e-Therapeutics’ Barlow hails deals with Novo Nordisk and...

Ray Barlow, chief executive of e-Therapeutics (LON:ETX), talks to Proactive’s Andrew Scott about the company’s unique approach to drug discovery, which uses computational techniques to find potential breakthrough new treatments. He also provided some insight into recent tie-ups with Denmark’s...

on 14/8/19

2 min read